Ampersand Capital Partners09.20.21
Precision Coating, a medical coatings service provider to interventional, orthopedic, and advanced surgical markets, has announced a merger with N2 Biomedical, a Bedford, MA-based company.
N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies.
"We are very excited to add N2's technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers. This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants," said Bill Ellerkamp, president of Precision Coating. "The two companies have a great deal of complementarity between market focus, customer overlap, product functional properties, and operational execution, not to mention geographic proximity."
Also, the company is pleased to welcome Keith Edwards, CEO of N2, and Heidi DeGrazia, CFO of N2, to the Precision Coating executive leadership team.
"The Precision Coating – N2 Biomedical merger pairs two firms with long histories of technology innovation, exceptional quality, continuous improvement, and a focus on supply performance," commented Keith Edwards. "Together we will excel as a trusted partner to the medical device community."
N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies.
"We are very excited to add N2's technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers. This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants," said Bill Ellerkamp, president of Precision Coating. "The two companies have a great deal of complementarity between market focus, customer overlap, product functional properties, and operational execution, not to mention geographic proximity."
Also, the company is pleased to welcome Keith Edwards, CEO of N2, and Heidi DeGrazia, CFO of N2, to the Precision Coating executive leadership team.
"The Precision Coating – N2 Biomedical merger pairs two firms with long histories of technology innovation, exceptional quality, continuous improvement, and a focus on supply performance," commented Keith Edwards. "Together we will excel as a trusted partner to the medical device community."
